Scale | ASTERIA I | ASTERIA II | GLACIAL | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Placebo | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo | Omalizumab 75 mg | Omalizumab 150 mg | Omalizumab 300 mg | Placebo | Omalizumab 300 mg | |
MOS-Sleep Scale, SPI-II, n | 80 | 77 | 80 | 81 | 79 | 82 | 82 | 79 | 83 | 252 |
Mean (SD)a | 47.8 (19.8) | 48.4 (17.8) | 49.2 (21.2) | 47.4 (19.3) | 47.4 (18.1) | 48.0 (18.6) | 48.5 (18.6) | 47.8 (17.8) | 47.9 (18.6) | 49.1 (18.9) |
UPDD Weekly Sleep Interference Score, n | 80 | 77 | 80 | 81 | 79 | 82 | 82 | 79 | 83 | 252 |
Mean (SD) | 12.6 (4.8) | 12.2 (5.3) | 12.1 (5.2) | 12.2 (4.5) | 12.1 (4.5) | 11.8 (5.4) | 11.4 (5.6) | 11.6 (4.3) | 11.2 (5.2) | 11.9 (4.8) |
CU-Q2oL Sleep Problems domain, n | 80 | 77 | 80 | 81 | 79 | 82 | 82 | 79 | 83 | 252 |
Mean (SD)b | 48.7 (23.6) | 46.8 (22.7) | 48.2 (25.2) | 49.3 (22.9) | 46.6 (19.9) | 45.1 (22.6) | 46.4 (23.7) | 49.4 (21.1) | 46.5 (21.8) | 46.4 (21.5) |